Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001893772 | SCV002171766 | uncertain significance | Brachyolmia-amelogenesis imperfecta syndrome | 2024-01-22 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 1225 of the LTBP3 protein (p.Ser1225Asn). This variant is present in population databases (rs141017996, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with LTBP3-related conditions. ClinVar contains an entry for this variant (Variation ID: 1399312). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002458761 | SCV002615147 | uncertain significance | Inborn genetic diseases | 2021-10-07 | criteria provided, single submitter | clinical testing | The p.S1225N variant (also known as c.3674G>A), located in coding exon 27 of the LTBP3 gene, results from a G to A substitution at nucleotide position 3674. The serine at codon 1225 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |